220 related articles for article (PubMed ID: 36739454)
1. Longitudinal DNA methylation analysis of adult-type IDH-mutant gliomas.
Ferreyra Vega S; Olsson Bontell T; Kling T; Jakola AS; Carén H
Acta Neuropathol Commun; 2023 Feb; 11(1):23. PubMed ID: 36739454
[TBL] [Abstract][Full Text] [Related]
2. Spatial heterogeneity in DNA methylation and chromosomal alterations in diffuse gliomas and meningiomas.
Ferreyra Vega S; Wenger A; Kling T; Olsson Bontell T; Jakola AS; Carén H
Mod Pathol; 2022 Nov; 35(11):1551-1561. PubMed ID: 35701666
[TBL] [Abstract][Full Text] [Related]
3. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ
J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459
[TBL] [Abstract][Full Text] [Related]
4. Isocitrate Dehydrogenase Mutations Are Associated with Different Expression and DNA Methylation Patterns of OLIG2 in Adult Gliomas.
Mo H; Magaki S; Deisch JK; Raghavan R
J Neuropathol Exp Neurol; 2022 Aug; 81(9):707-716. PubMed ID: 35856894
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.
Christensen BC; Smith AA; Zheng S; Koestler DC; Houseman EA; Marsit CJ; Wiemels JL; Nelson HH; Karagas MR; Wrensch MR; Kelsey KT; Wiencke JK
J Natl Cancer Inst; 2011 Jan; 103(2):143-53. PubMed ID: 21163902
[TBL] [Abstract][Full Text] [Related]
7. Suppression of antitumor immune signatures and upregulation of VEGFA as IDH-mutant gliomas progress to higher grade.
Grewal EP; Richardson LGK; Sun J; Ramapriyan R; Martinez-Lage M; Miller JJ; Cahill DP; Choi BD; Curry WT
Neurosurg Focus; 2024 Feb; 56(2):E2. PubMed ID: 38301244
[TBL] [Abstract][Full Text] [Related]
8. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.
Suwala AK; Stichel D; Schrimpf D; Kloor M; Wefers AK; Reinhardt A; Maas SLN; Kratz CP; Schweizer L; Hasselblatt M; Snuderl M; Abedalthagafi MSJ; Abdullaev Z; Monoranu CM; Bergmann M; Pekrun A; Freyschlag C; Aronica E; Kramm CM; Hinz F; Sievers P; Korshunov A; Kool M; Pfister SM; Sturm D; Jones DTW; Wick W; Unterberg A; Hartmann C; Dodgshun A; Tabori U; Wesseling P; Sahm F; von Deimling A; Reuss DE
Acta Neuropathol; 2021 Jan; 141(1):85-100. PubMed ID: 33216206
[TBL] [Abstract][Full Text] [Related]
9. Region-specific DNA hydroxymethylation along the malignant progression of IDH-mutant gliomas.
Hana T; Mukasa A; Nomura M; Nagae G; Yamamoto S; Tatsuno K; Ueda H; Fukuda S; Umeda T; Tanaka S; Nejo T; Kitagawa Y; Yamazawa E; Takahashi S; Koike T; Kushihara Y; Takami H; Takayanagi S; Aburatani H; Saito N
Cancer Sci; 2024 May; 115(5):1706-1717. PubMed ID: 38433527
[TBL] [Abstract][Full Text] [Related]
10. Global DNA methylation profiling reveals chromosomal instability in IDH-mutant astrocytomas.
Liu Y; Sathe AA; Abdullah KG; McBrayer SK; Adams SH; Brenner AJ; Hatanpaa KJ; Viapiano MS; Xing C; Walker JM; Richardson TE
Acta Neuropathol Commun; 2022 Mar; 10(1):32. PubMed ID: 35264242
[TBL] [Abstract][Full Text] [Related]
11. Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis.
Hasselblatt M; Jaber M; Reuss D; Grauer O; Bibo A; Terwey S; Schick U; Ebel H; Niederstadt T; Stummer W; von Deimling A; Paulus W
J Neuropathol Exp Neurol; 2018 Jun; 77(6):422-425. PubMed ID: 29444314
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas.
Liu Y; Chen H; Li G; Zhang J; Yao K; Wu C; Li S; Qiu X
Cancer Biol Med; 2022 Nov; 19(10):1477-86. PubMed ID: 36350001
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of H3 K27M-mutant gliomas in adults.
Meyronet D; Esteban-Mader M; Bonnet C; Joly MO; Uro-Coste E; Amiel-Benouaich A; Forest F; Rousselot-Denis C; Burel-Vandenbos F; Bourg V; Guyotat J; Fenouil T; Jouvet A; Honnorat J; Ducray F
Neuro Oncol; 2017 Aug; 19(8):1127-1134. PubMed ID: 28201752
[TBL] [Abstract][Full Text] [Related]
14. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
[TBL] [Abstract][Full Text] [Related]
15. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.
Gorovets D; Kannan K; Shen R; Kastenhuber ER; Islamdoust N; Campos C; Pentsova E; Heguy A; Jhanwar SC; Mellinghoff IK; Chan TA; Huse JT
Clin Cancer Res; 2012 May; 18(9):2490-501. PubMed ID: 22415316
[TBL] [Abstract][Full Text] [Related]
16. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.
Mukasa A; Takayanagi S; Saito K; Shibahara J; Tabei Y; Furuya K; Ide T; Narita Y; Nishikawa R; Ueki K; Saito N
Cancer Sci; 2012 Mar; 103(3):587-92. PubMed ID: 22136423
[TBL] [Abstract][Full Text] [Related]
17. The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.
Corell A; Ferreyra Vega S; Hoefling N; Carstam L; Smits A; Olsson Bontell T; Björkman-Burtscher IM; Carén H; Jakola AS
BMC Cancer; 2020 May; 20(1):450. PubMed ID: 32434559
[TBL] [Abstract][Full Text] [Related]
18. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
Macaulay RJ
Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
[TBL] [Abstract][Full Text] [Related]
19. MR imaging phenotype correlates with extent of genome-wide copy number abundance in IDH mutant gliomas.
Wu CC; Jain R; Neto L; Patel S; Poisson LM; Serrano J; Ng V; Patel SH; Placantonakis DG; Zagzag D; Golfinos J; Chi AS; Snuderl M
Neuroradiology; 2019 Sep; 61(9):1023-1031. PubMed ID: 31134296
[TBL] [Abstract][Full Text] [Related]
20. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.
Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A
Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
